A Randomised, Open, Parallel-group Phase III Biosimilarity Study to Assess the Long-term Safety, Focusing on Immunogenicity, of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.
Latest Information Update: 15 Jun 2020
Price :
$35 *
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Sponsors Rechon Life Science
- 14 Jun 2020 Status changed from recruiting to completed.
- 14 Jun 2020 This trial has been completed in Poland dated (global end of the trial 2019-12-17 )according to European Clinical Trials Database
- 17 Jan 2020 This trial has been completed in Germany , according to European Clinical Trials Database.